Active	Status	Sponsor type	Region	Phase	Filter
1 Active 0 Inactive 1 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

1 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Bouffet
NEWEL, NCT05222165 / 2021-005614-34: Study With Infigratinib in Subjects With Advanced Solid and CNS Tumors or Recurrent or Progressive Low-Grade Glioma With Selected FGFR1-3 Alterations	Withdrawn	1b/2	51	Europe, Canada, US	Infigratinib, BGJ398	Helsinn Healthcare SA, Labcorp Drug Development Inc	Advanced Solid Tumor, CNS Tumor, Recurrent WHO Grade II Glioma	12/22	12/22